Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Baraliakos, Xenofon" or (type any "bookEditor journalEditor issueEditor" and editor="Bara...

Add to list
- Journal Article
- A1
Achievement of remission endpoints with secukinumab over 3 years in active ankylosing spondylitis : pooled analysis of two phase 3 studies

Xenofon Baraliakos, Filip Van den Bosch (UGent) , Pedro M. Machado, Lianne S. Gensler, Helena Marzo-Ortega, Bintu Sherif, Erhard Quebe-Fehling, Brian Porter, Corine Gaillez and Atul Deodhar

(2021) RHEUMATOLOGY AND THERAPY.
Add to list
- Journal Article
- A1
- open access
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors : a consensus statement

Peter Nash, Andreas Kerschbaumer, Thomas Doerner, Maxime Dougados, Roy M. Fleischmann, Klaus Geissler, Iain McInnes, Janet E. Pope, Desiree van der Heijde, Michaela Stoffer-Marx, et al.

(2021) ANNALS OF THE RHEUMATIC DISEASES. 80(1). p.71-87
Add to list
- Journal Article
- A1
- open access
Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

Robert B. M. Landewe, Desiree van der Heijde, Maxime Dougados, Xenofon Baraliakos, Filip Van den Bosch (UGent) , Karl Gaffney, Lars Bauer, Bengt Hoepken, Owen R. Davies, Natasha de Peyrecave, et al.

(2020) ANNALS OF THE RHEUMATIC DISEASES. 79(7). p.920-928
Add to list
- Journal Article
- A1
- open access
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Maxime Dougados, James Cheng-Chung Wei, Robert Landewe, Joachim Sieper, Xenofon Baraliakos, Filip Van den Bosch (UGent) , Walter P. Maksymowych, Joerg Ermann, Jessica A. Walsh, Tetsuya Tomita, et al.

(2020) ANNALS OF THE RHEUMATIC DISEASES. 79(2). p.176-185
Add to list
- Journal Article
- A1
- open access
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis : 5-year results from the phase III MEASURE 1 extension study

Xenofon Baraliakos, Juergen Braun, Atul Deodhar, Denis Poddubnyy, Alan Kivitz, Hasan Tahir, Filip Van den Bosch (UGent) , Evie-Maria Delicha, Zsolt Talloczy and Anke Fierlinger

(2019) RMD OPEN. 5(2).
Add to list
MRI lesions in the sacroiliac joints of patients with spondyloarthritis : an update of definitions and validation by the ASAS MRI working group

Walter P Maksymowych, Robert GW Lambert, Mikkel Ostergaard, Susanne Juhl Pedersen, Pedro M Machado, Ulrich Weber, Alexander N Bennett, Juergen Braun, Ruben Burgos-Vargas, Manouk de Hooge (UGent) , et al.

(2019) ANNALS OF THE RHEUMATIC DISEASES. 78(11). p.1550-1558
Add to list
- Journal Article
- A1
- open access
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target : 2017 update of recommendations by an international task force

Josef S Smolen, Monika Schoels, Juergen Braun, Maxime Dougados, Oliver FitzGerald, Dafna D Gladman, Arthur Kavanaugh, Robert Landewe, Philip Mease, Joachim Sieper, et al.

(2018) ANNALS OF THE RHEUMATIC DISEASES. 77(1). p.3-17
Add to list
- Journal Article
- A2
- open access
Efficacy and safety of biological and targeted-synthetic DMARDs : a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

Alexandre Sepriano, Andrea Regel, Désirée van der Heijde, Jürgen Braun, Xenofon Baraliakos, Robert Landewé, Filip Van den Bosch (UGent) , Louise Falzon and Sofia Ramiro

(2017) RMD OPEN. 3(1).
Add to list
- Journal Article
- A2
- open access
Efficacy and safety of non-pharmacological and non-biological pharmacological treatment : a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

Andrea Regel, Alexandre Sepriano, Xenofon Baraliakos, Désirée van der Heijde, Jürgen Braun, Robert Landewé, Filip Van den Bosch (UGent) , Louise Falzon and Sofia Ramiro

(2017) RMD OPEN. 3(1).
Add to list
- Journal Article
- A1
- open access
ASAS definition for sacroiliitis on MRI in SpA : applicable to children?

Nele Herregods (UGent) , Jo Dehoorne (UGent) , Filip Van den Bosch (UGent) , Jacob Lester Jaremko, Joke Van Vlaenderen (UGent) , Rik Joos, Xenofon Baraliakos, Gaëlle Varkas (UGent) , Koenraad Verstraete (UGent) , Dirk Elewaut (UGent) , et al.

(2017) PEDIATRIC RHEUMATOLOGY. 15.

Academic Bibliography

Achievement of remission endpoints with secukinumab over 3 years in active ankylosing spondylitis : pooled analysis of two phase 3 studies

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors : a consensus statement

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction

Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis : 5-year results from the phase III MEASURE 1 extension study

MRI lesions in the sacroiliac joints of patients with spondyloarthritis : an update of definitions and validation by the ASAS MRI working group

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target : 2017 update of recommendations by an international task force

Efficacy and safety of biological and targeted-synthetic DMARDs : a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

Efficacy and safety of non-pharmacological and non-biological pharmacological treatment : a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis

ASAS definition for sacroiliitis on MRI in SpA : applicable to children?

Contents

Support

Contact